Journey Medical Corporation (DERM) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

17/25

Growth 4 Margin 5 Expansion 4 Platform 1 Financial 3

latest quarter score

Earnings Reports

17
Journey Medical (DERM) Q2 2026: 23% Revenue Growth Accelerates Rosacea Franchise Expansion
August 13, 2026
16
Journey Medical (DERM) Q1 2026: Ambrosie Revenue Jumps 200% as Payer Access Hits 169 Million Lives
May 14, 2026
17
Journey Medical (DERM) Q4 2025: MROSI Scripts Annualize at 126,000, Driving Margin Expansion and Brand Penetration
March 26, 2026
16
Journey Medical (DERM) Q3 2025: Amrosi Prescriptions Jump 146%, Driving Operating Leverage
November 13, 2025
18
Journey Medical (DERM) Q2 2025: Amrosi Drives $2.8M Launch, Lifts Gross Margin to 67%
August 13, 2025
11
Journey Medical (DERM) Q1 2025: Emrosi Launch Drives Strategic Shift Toward Profitability
May 14, 2025
15
Journey Medical (DERM) Q4 2024: Emrosi Launch Sets Stage for Transformational Growth Amid Legacy Pressures
March 26, 2025

Browse all companies